Evidence map›Paper›PMID 40576244›Full record

ArticleGut microbes2025

Gut microbial metabolite butyrate suppresses hepatocellular carcinoma growth via CXCL11-dependent enhancement of natural killer cell infiltration.

Menghan Zhang, Xuefeng Huang, Yanlong Zhang, Minghang Yu, Xiaoxue Yuan, Yifan Xu, Lei Ma, Xi Wang, Huichun Xing

Abstract read
In one paragraph

Article in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. ISME communications · 2026
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Menghan ZhangCenter of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Xuefeng HuangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing, China.
Yanlong ZhangShanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
Minghang YuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing, China.
Xiaoxue YuanNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing, China.
Yifan XuCenter of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Lei MaCenter of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Xi WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing, China.
Huichun XingCenter of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-9111-9669

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gut microbiota-derived butyrate plays a vital role in attenuating hepatocellular carcinoma (HCC) in murine models. However, the precise molecular mechanisms by which butyrate exerts its effects are largely undefined. Plasma short-chain fatty acids (SCFAs) were quantitatively measured by using gas chromatography-mass spectrometry (GC-MS) to access their association with HCC prognosis. Tumor-infiltrating immune cells were characterized by flow cytometry. The interactions between butyrate and natural killer (NK) cells were studied using in vitro assays, including migration, cytotoxic degranulation, and co-culture experiments. In vivo validation was conducted through neutralization experiments. The molecular pathways regulated by butyrate were further investigated by employing RNA sequencing (RNA-seq), chromatin immunoprecipitation sequencing (ChIP-seq), and Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq). A positive correlation was observed between elevated plasma butyrate levels and improved prognosis in HCC patients. Notably, butyrate inhibited tumor progression by enhancing NK cell infiltration into tumor tissues. Mechanistically, butyrate stimulated cytokine secretion, notably significantly enhancing the production of the chemokine CXCL11, thereby facilitating NK cell infiltration. Gene Set Enrichment Analysis (GSEA) of hepatic tumor cell lines revealed that the chemokine signaling and NK cell-mediated cytotoxicity pathways were upregulated following butyrate stimulation. Furthermore, transcriptomic and epigenomic analyses showed that exposure to butyrate induced de novo chromatin accessibility and enhancer remodeling, regulated by STAT family transcription factors. Our study demonstrated that butyrate was able to enhance the expression of CXCL11. This is likely attributed to chromatin remodeling, and then promoting NK cell infiltration and exerting effective anti-tumor effects on HCC.

Indexed as

ButyratesCarcinoma, HepatocellularChemokine CXCL11Gastrointestinal MicrobiomeKiller Cells, NaturalLiver NeoplasmsAnimalsCell Line, TumorFemaleHumansMaleMiceMice, Inbred C57BLButyratesChemokine CXCL11butyrateepigeneticGut microbiotahepatocellular carcinomanatural killer cells

Identifiers

PMID40576244
PMCPMC12218501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.